Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

2.86
-0.1100-3.70%
Post-market: 2.880.0201+0.70%19:55 EDT
Volume:4.92M
Turnover:14.35M
Market Cap:554.84M
PE:-3.76
High:2.99
Open:2.99
Low:2.86
Close:2.97
52wk High:6.44
52wk Low:2.56
Shares:194.00M
Float Shares:164.00M
Volume Ratio:1.45
T/O Rate:3.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7600
EPS(LYR):-0.9999
ROE:-28.87%
ROA:-17.20%
PB:1.17
PE(LYR):-2.86

Loading ...

Altimmune Initiates Performa Phase 3 Trial of Pemvidutide in Patients with Mash

THOMSON REUTERS
·
Aug 03

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

GlobeNewswire
·
Jul 30

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (GOVX), Incyte (INCY) and Altimmune (ALT)

TIPRANKS
·
Jul 29

U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal

Reuters
·
Jul 29

U.S. Stocks on the MOVE-Visa, CMS Energy, Ecolab

Reuters
·
Jul 29

Barclays says trial data highlights meaningful opportunity for Altimmune in AUD

TIPRANKS
·
Jul 29

H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune

TIPRANKS
·
Jul 28

Leerink remains bullish on Altimmune following ‘positive’ AUD trial results

TIPRANKS
·
Jul 28

Unusually active option classes on open July 28th

TIPRANKS
·
Jul 28

Altimmune's Investigational Alcohol Use Disorder Drug Meets Primary Endpoint in Phase 2 Study

MT Newswires Live
·
Jul 28

Altimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide

Dow Jones
·
Jul 28

Altimmune Jumps as Experimental Obesity Drug Shows Benefit in Alcohol Use Disorder Study

Reuters
·
Jul 28

Altimmune Shares up 17% Premarket as Co's Drug Meets Main Goal of Mid-Stage Study for Alcohol Use Disorder

THOMSON REUTERS
·
Jul 28

Altimmune's Drug Meets Main Goal of Mid-stage Study for Alcohol Use Disorder

Reuters
·
Jul 28

Altimmune - to Request End-of-Phase 2 Meeting with FDA for Pemvidutide in AUD

THOMSON REUTERS
·
Jul 28

Altimmune - Pemvidutide Meets FDA-Recognized Registrational Endpoints in Phase 2 Trial

THOMSON REUTERS
·
Jul 28

Altimmune Announces Positive Topline Results from Reclaim Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

THOMSON REUTERS
·
Jul 28

Altimmune - Pemvidutide 2.4 Mg Achieves Significant Reduction in Heavy Drinking Days in Phase 2 Trial

THOMSON REUTERS
·
Jul 28

Altimmune - Pemvidutide Demonstrates Generally Favorable Tolerability Profile in Phase 2 Trial

THOMSON REUTERS
·
Jul 28

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

GlobeNewswire
·
Jul 15